Biomark Diagnostics Inc. BMKDF
Set alert
0.34 USD 0.00 0.00%
At close · Nov 2
0.3358 Day range 0.3358
0.2259 52-week range 0.5044
- YTD
- -2.07%
- 1 year
- +39.86%
- Open
- 0.3358
- Prev close
- 0.3358
- Mkt cap
- 35.76M
- Vol
- 200
- Avg vol
- 1.92K
- EPS
- -0.02
- P/E
- 0.00
More statistics
- Low
- 0.3358
- High
- 0.3358
2Y chart
Signals (102)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 23, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 8, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 4 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 4 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 4 weeks ago |
| SMA: Bearish | Sep 30, 2026 | 1 month ago |
| SMA: Bullish | Sep 24, 2026 | 1 month ago |
| SMA: Bullish | Sep 24, 2026 | 1 month ago |
| RSI: Overbought | Sep 24, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 11, 2026 | 1 month ago |
| RSI: Oversold | Sep 2, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 21, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| RSI: Overbought | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 3 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 3 months ago |
| SMA: Bearish | Aug 3, 2026 | 3 months ago |
| MACD: Sell Signal | Aug 3, 2026 | 3 months ago |
Newest 20 of 102.
News
- BioMark Announces Participation in upcoming MSACL 2026 and BIOHorizon 2026 Life Sciences Conferences
- BioMark's Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy
- BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day
- BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test
- BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform
- BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum
- BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology
- BioMark: 2025 Achievements & 2026 Vision
- BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors
- BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program
Your note
Sign in to keep a note on BMKDF — it syncs with the Stock Master app.